2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12B.06 Efficacy of Lorlatinib in Advanced ALK-Positive Non-Small Cell Lung Cancer Patients in Thailand: A Multicenter Study

EP.12B.06 Efficacy of Lorlatinib in Advanced ALK-Positive Non-Small Cell Lung Cancer Patients in Thailand: A Multicenter Study

Back to course

Pdf Summary

The study focuses on evaluating the efficacy of lorlatinib, a third-generation ALK inhibitor, in treating advanced ALK-positive non-small cell lung cancer (NSCLC) patients in Thailand. Conducted by Kunlatida Maneenil, MD, and several co-authors across multiple Thai medical centers, the research involves a retrospective cohort of 26 patients treated from April 2019 to February 2021 under the Named Patient Use program.<br /><br />The study participants were predominantly female (69.2%) and non-smokers (76.9%), with a median age of 61 years. Most patients (84.6%) had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1, indicating they were fully active or restricted in physically strenuous activity but ambulatory. Lorlatinib was administered primarily as a later-line treatment, with the patients experiencing varying sites of metastasis, including brain, bone, and lungs.<br /><br />Investigators primarily measured the time to treatment failure (TTF) and secondarily assessed overall survival (OS) and toxicity profiles. The median follow-up duration for the study was 51.2 months. Results showed a median TTF of 6.8 months, with an objective response rate of 34.6% and a disease control rate of 80.8%. The study reported a median overall survival since starting lorlatinib at 42.7 months.<br /><br />Treatment-related toxicities occurred in 57.7% of the patients, where dyslipidemia was the most common followed by leg edema and weight increase. The study found that the clinical efficacy and safety profile of lorlatinib was consistent with findings from earlier clinical trials, highlighting its effectiveness even in heavily pretreated patient populations. In conclusion, lorlatinib offers significant clinical benefits and demonstrates a favorable tolerability profile.

Asset Subtitle

Kunlatida Maneenil

Meta Tag

Speaker Kunlatida Maneenil

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

lorlatinib

ALK inhibitor

non-small cell lung cancer

NSCLC

Thailand

retrospective cohort

treatment efficacy

treatment toxicity

clinical trials

oncology